Improving the Renal Profile of a HIV Drug Combination Through Prodrug Alteration

Authors

Derek E. Murrell, East Tennessee State University
Sam Harirforoosh, Chapman UniversityFollow

Document Type

Editorial

Publication Date

2016

Abstract

"Human immunodeficiency virus (HIV) continues to alter the lives of countless individuals, who once infected, live on a continuum between viral suppression and acquired immunodeficiency syndrome. The former being achieved via the use of various antiretrovirals beginning with the release of zidovudine over a quarter-century ago; whereas the latter may result from treatment failure or lack of treatment such as in the absence of diagnosis or the inaccessibility of medication. As no cure is yet available, regimens must be continued lifelong. Thus, contemporary treatment is given as a combination of agents from various antiretroviral drug classes in an effort to reduce the likelihood of viral resistance. Although highly effective in reducing plasma HIV viral load, side effect profiles and safety issues can limit the use of some drugs.[1]"

Comments

This article was originally published in Journal of Integrative Nephrology and Andrology, volume 3, in 2016. https://doi.org/10.4103/2394-2916.175388

Recommended Citation

Derek E. Murrell and Sam Harirforoosh. 2016. Improving the renal profile of a HIV drug combination through prodrug alteration. Journal of Integrative Nephrology and Andrology. 3:1-2 https://doi.org/10.4103/2394-2916.175388

Copyright

Lippincott Williams & Wilkins, Inc.

Creative Commons License

This work is licensed under a Creative Commons Attribution-Noncommercial-Share Alike 3.0 License.